-
1.发明授权Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases 有权使用可溶形式的CD83和编码它们的核酸用于治疗或预防疾病公开(公告)号：US07893200B2
公开(公告)日：2011-02-22
申请号：US10535522
申请日：2003-11-19
CPC分类号： C07K14/70503 , A61K38/00 , A61K38/1774 , C07K16/2896
摘要： The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.
摘要翻译： 本发明提供使用可溶形式的CD83和编码它们的核酸来治疗由涉及树突状细胞，T细胞和/或B细胞的细胞免疫应答的功能障碍或不期望的功能引起的疾病。 此外，本发明提供了特别适合于所述目的的可溶性CD83分子，针对所述特异性可溶性CD83蛋白的抗体以及包含所述抗体的测定方法和试剂盒。
-
2.发明申请Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases 有权使用可溶性形式的cd83和编码它们的核酸用于治疗或预防疾病公开(公告)号：US20070167607A1
公开(公告)日：2007-07-19
申请号：US10535522
申请日：2003-11-19
IPC分类号： C07K14/705 , G01N33/53 , C07H21/04 , C12P21/06 , C12N1/21
CPC分类号： C07K14/70503 , A61K38/00 , A61K38/1774 , C07K16/2896
摘要： The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.
摘要翻译： 本发明提供使用可溶形式的CD83和编码它们的核酸来治疗由涉及树突状细胞，T细胞和/或B细胞的细胞免疫应答的功能障碍或不期望的功能引起的疾病。 此外，本发明提供了特别适合于所述目的的可溶性CD83分子，针对所述特异性可溶性CD83蛋白的抗体以及包含所述抗体的测定方法和试剂盒。
-
3.发明授权Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same 有权编码可溶性形式的CD83的重组表达载体的核酸，转化/转染的宿主细胞和含有它们的药物组合物公开(公告)号：US09102726B2
公开(公告)日：2015-08-11
申请号：US10382397
申请日：2003-03-06
IPC分类号： C07K16/28 , C07K14/705 , A61K48/00 , A61K38/00
CPC分类号： C07K16/2803 , A61K38/00 , A61K48/00 , C07K14/70503 , G01N2333/70503
摘要： The present invention provides methods of using soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases caused by the dysfunction or undesired function of a cellular immune response involving T cells. The invention moreover provides soluble CD83 proteins, specifically suited for said purpose, nucleic acids and vectors encoding said CD83 proteins, cells transformed/transfected with the nucleic acids or vectors, methods for producing said CD83 proteins, pharmaceutical compositions containing said CD83 proteins, nucleic acids or vectors, and antibodies against said soluble CD83 proteins and assay methods and kits comprising said antibodies.
摘要翻译： 本发明提供了使用可溶形式的CD83和编码它们的核酸用于治疗或预防由涉及T细胞的细胞免疫应答的功能障碍或不期望的功能引起的疾病的方法。 此外，本发明提供了特别适用于所述目的的可溶性CD83蛋白，编码所述CD83蛋白的核酸和载体，用核酸或载体转化/转染的细胞，用于产生所述CD83蛋白的方法，含有所述CD83蛋白的药物组合物， 或载体，以及针对所述可溶性CD83蛋白的抗体以及包含所述抗体的测定方法和试剂盒。
-
4.发明申请Soluble CD83 proteins and use thereof for the treatment and prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells 有权可溶性CD83蛋白及其用于治疗和预防由涉及T细胞的细胞免疫应答的功能障碍或不期望功能引起的疾病或医学病症公开(公告)号：US20070212370A1
公开(公告)日：2007-09-13
申请号：US11699918
申请日：2007-01-30
IPC分类号： A61K39/00 , A61K31/7052 , A61K39/15 , C12N15/00 , C12P1/04 , G01N33/574 , C12N5/06 , C07K14/00 , A61K38/00
CPC分类号： C07K14/70503 , A61K38/00 , A61K48/00 , C07K16/2803 , G01N2333/70503
摘要： The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving T cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.
摘要翻译： 本发明提供了使用可溶形式的CD83和编码它们的核酸来治疗由涉及T细胞的细胞免疫应答的功能障碍或不期望的功能引起的疾病。 此外，本发明提供了特别适合于所述目的的可溶性CD83分子，针对所述特异性可溶性CD83蛋白的抗体以及包含所述抗体的测定方法和试剂盒。
-
5.发明授权Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells 有权可溶性CD83蛋白及其用于治疗或预防由涉及T细胞的细胞免疫反应的功能障碍或不期望的功能引起的疾病或医学病症公开(公告)号：US07169898B2
公开(公告)日：2007-01-30
申请号：US10309611
申请日：2002-12-04
CPC分类号： C07K14/70503 , A61K38/00 , A61K48/00 , C07K16/2803 , G01N2333/70503
摘要： The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving T cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.
摘要翻译： 本发明提供了使用可溶形式的CD83和编码它们的核酸来治疗由涉及T细胞的细胞免疫应答的功能障碍或不期望的功能引起的疾病。 此外，本发明提供了特别适合于所述目的的可溶性CD83分子，针对所述特异性可溶性CD83蛋白的抗体以及包含所述抗体的测定方法和试剂盒。
-
6.发明授权Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases 有权使用可溶形式的CD83和编码它们的核酸用于治疗或预防疾病公开(公告)号：US08759505B2
公开(公告)日：2014-06-24
申请号：US13011380
申请日：2011-01-21
CPC分类号： C07K14/70503 , A61K38/00 , A61K38/1774 , C07K16/2896
摘要： The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.
摘要翻译： 本发明提供使用可溶形式的CD83和编码它们的核酸来治疗由涉及树突状细胞，T细胞和/或B细胞的细胞免疫应答的功能障碍或不期望的功能引起的疾病。 此外，本发明提供了特别适合于所述目的的可溶性CD83分子，针对所述特异性可溶性CD83蛋白的抗体以及包含所述抗体的测定方法和试剂盒。
-
7.发明授权Soluble CD83 proteins and use thereof for the treatment and prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells 有权可溶性CD83蛋白及其用于治疗和预防由涉及T细胞的细胞免疫应答的功能障碍或不期望功能引起的疾病或医学病症公开(公告)号：US08124099B2
公开(公告)日：2012-02-28
申请号：US11699918
申请日：2007-01-30
CPC分类号： C07K14/70503 , A61K38/00 , A61K48/00 , C07K16/2803 , G01N2333/70503
摘要： The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving T cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.
摘要翻译： 本发明提供了使用可溶形式的CD83和编码它们的核酸来治疗由涉及T细胞的细胞免疫应答的功能障碍或不期望的功能引起的疾病。 此外，本发明提供了特别适合于所述目的的可溶性CD83分子，针对所述特异性可溶性CD83蛋白的抗体以及包含所述抗体的测定方法和试剂盒。
-
公开(公告)号：US09822377B2
公开(公告)日：2017-11-21
申请号：US14113844
申请日：2012-04-27
CPC分类号： C12N15/85 , C12N15/86 , C12N2710/10041
摘要： The present invention provides a mutant CD83 promoter comprising the promoter/enhancer regions of human CD83 promoter and being dendritic cell-specific, and the use thereof, specifically for the treatment or prevention of diseases or medical conditions related to malignancy, autoimmunity or prevention of transplant rejections.
-
公开(公告)号：US20140050748A1
公开(公告)日：2014-02-20
申请号：US14113844
申请日：2012-04-27
IPC分类号： C12N15/85
CPC分类号： C12N15/85 , C12N15/86 , C12N2710/10041
摘要： The present invention provides a mutant CD83 promoter comprising the promoter/enhancer regions of human CD83 promoter and being dendritic cell-specific, and the use thereof, specifically for the treatment or prevention of diseases or medical conditions related to malignancy, autoimmunity or prevention of transplant rejections.
摘要翻译： 本发明提供了包含人CD83启动子的启动子/增强子区并且是树突状细胞特异性的突变体CD83启动子，以及其用于治疗或预防与恶性肿瘤，自身免疫或预防移植有关的疾病或医学病症的用途 拒绝
-
公开(公告)号：US20120269797A1
公开(公告)日：2012-10-25
申请号：US13384024
申请日：2010-07-15
IPC分类号： A61K38/55 , C07H15/24 , A61K31/704 , C07D207/28 , A61K31/4015 , C07K5/083 , C07F5/04 , A61K31/436 , A61K31/5377 , A61K39/395 , A61P37/08 , A61P11/06 , A61P37/06 , A61P37/00 , A61P21/04 , A61P25/00 , A61P1/00 , A61P19/04 , A61P17/00 , A61P29/00 , A61P3/10 , A61P1/04 , A61P17/06 , C07K5/103
摘要： Proteasome inhibitors (PI) are used for inhibiting the maturation of dendritic cells (DZ) and thus in the treatment or the prophylaxis of allergies, asthma, tissue or transplant rejection or autoimmune diseases. The concentration of the proteasome inhibitors lies preferably in the range of 10 nM to 10 μM, based on the peripheral blood or the cytoplasm.
摘要翻译： 蛋白酶体抑制剂（PI）用于抑制树突状细胞（DZ）的成熟，从而用于治疗或预防过敏，哮喘，组织或移植排斥或自身免疫性疾病。 基于外周血或细胞质，蛋白酶体抑制剂的浓度优选在10nM至10μM的范围内。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.03 秒)
